StockData
NCELNasdaqPharmaceutical PreparationsFiscal year ends December 31

NewcelX Ltd.

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 29, 2026
$2.63+0.13 (+5.20%)

Close on Oct 19, 2026

Market cap
–
P/E (TTM)
1.2
Dividend yield
–

NewcelX Ltd. revenue by segment

No segment breakdown reported

NewcelX does not break out revenue by segment, region or product in the tagged data of its filings for this period type.